ロード中...
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibi...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3660082/ https://ncbi.nlm.nih.gov/pubmed/23504948 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt070 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|